<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03006926</url>
  </required_header>
  <id_info>
    <org_study_id>E7080-J081-116</org_study_id>
    <secondary_id>KEYNOTE 524</secondary_id>
    <secondary_id>2018-000522-55</secondary_id>
    <nct_id>NCT03006926</nct_id>
  </id_info>
  <brief_title>A Trial of Lenvatinib Plus Pembrolizumab in Subjects With Hepatocellular Carcinoma</brief_title>
  <official_title>An Open-Label Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Subjects With Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label Phase 1b study designed to evaluate the tolerability and safety of
      lenvatinib in combination with pembrolizumab in participants with hepatocellular carcinoma
      (HCC). The Expansion part of the study will evaluate objective response rate and duration of
      response by modified Response Evaluation Criteria In Solid Tumors for HCC (mRECIST) and
      RECIST 1.1 based on independent imaging review
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2017</start_date>
  <completion_date type="Anticipated">February 28, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with any serious adverse event and number of participants with any non-serious adverse event.</measure>
    <time_frame>For each participant, from the first participant first dose until 30 days after the last dose (up to approximately 2 years)</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered an investigational product. An AE does not necessarily have a causal relationship with the medicinal product. A serious adverse event (SAE) is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; or is a congenital anomaly/birth defect.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT) of lenvatinib and pembrolizumab during Cycle 1</measure>
    <time_frame>Up to 21 Days (Cycle 1)</time_frame>
    <description>A DLT is defined as any of the following: (1) any of the hematological or nonhematological toxicities specified in the protocol that are considered to be at least possibly related to lenvatinib and/or pembrolizumab occurring during Cycle 1; (2) failure to administer greater than or equal to 75% of the planned dosage of lenvatinib as a result of treatment-related toxicity during Cycle 1; (3) participants who discontinue treatment due to treatment-related toxicity in Cycle 1; (4) greater than 2 week delay in starting pembrolizumab in Cycle 2 because of a treatment-related toxicity, even if the toxicity does not meet DLT criteria&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) based on modified Response Evaluation Criteria In Solid Tumors (mRECIST)</measure>
    <time_frame>From date of first dose of study drug until disease progression, development of unacceptable toxicity, withdrawal of consent, or up to approximately 2 years</time_frame>
    <description>ORR is defined as the proportion of participant who have BOR of CR or PR at the time of data cutoff. Responses (PR or CR) should be confirmed no less than 4 weeks after the initial response. Assessment and definition of BOR is based on mRECIST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) based on mRECIST</measure>
    <time_frame>From the first documentation of complete response (CR) or partial response (PR) to the date of first documentation of disease progression or death (whichever occurs first), or up to approximately 2 years</time_frame>
    <description>From the first documentation of complete response (CR) or partial response (PR) to the date of first documentation of disease progression or death (whichever occurs first). Assessment and definition of PD is based on mRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean maximum concentration (Cmax) of lenvatinib</measure>
    <time_frame>Cycle 1, Day 1: predose of pembrolizumab; 1, 2, 4, 8, and 24 hours postdose of lenvatinib. Cycle 1, Day 15: predose of lenvatinib; 1, 2, 4, 8, and 24 hours postdose of lenvatinib</time_frame>
    <description>Blood samples will be collected at the designated time points. Cmax is the highest concentration of drug in the plasma that is measured after a dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time to reach maximum concentration (Tmax) of lenvatinib</measure>
    <time_frame>Cycle 1, Day 1: predose of pembrolizumab; 1, 2, 4, 8, and 24 hours postdose of lenvatinib. Cycle 1, Day 15: predose of lenvatinib; 1, 2, 4, 8, and 24 hours postdose of lenvatinib</time_frame>
    <description>Blood samples will be collected at the designated time points. Tmax is the time to the highest concentration of lenvatinib in the plasma that is measured after a dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean terminal half-life (t1/2) of lenvatinib</measure>
    <time_frame>Cycle 1, Day 1: predose of pembrolizumab; 1, 2, 4, 8, and 24 hours postdose of lenvatinib. Cycle 1, Day 15: predose of lenvatinib; 1, 2, 4, 8, and 24 hours postdose of lenvatinib</time_frame>
    <description>Blood samples will be collected at the designated time points. t1/2 is the time taken for the plasma concentration to fall to half its original value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean area under the drug concentration-time curve (AUC) of lenvatinib</measure>
    <time_frame>Cycle 1, Day 1: predose of pembrolizumab; 1, 2, 4, 8, and 24 hours postdose of lenvatinib. Cycle 1, Day 15: predose of lenvatinib; 1, 2, 4, 8, and 24 hours postdose of lenvatinib</time_frame>
    <description>Blood samples will be collected at the designated time points. AUC represents the overall amount of drug in the plasma after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean apparent total clearance (CL/F) of lenvatinib</measure>
    <time_frame>Cycle 1, Day 1: predose of pembrolizumab; 1, 2, 4, 8, and 24 hours postdose of lenvatinib. Cycle 1, Day 15: predose of lenvatinib; 1, 2, 4, 8, and 24 hours postdose of lenvatinib</time_frame>
    <description>Blood samples will be collected at the designated time points. Apparent clearance is defined as the rate of lenvatinib elimination divided by plasma concentration, giving a volume of plasma from which drug is completely removed per unit of time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean apparent volume of distribution (Vz/F) of lenvatinib</measure>
    <time_frame>Cycle 1, Day 1: predose of pembrolizumab; 1, 2, 4, 8, and 24 hours postdose of lenvatinib. Cycle 1, Day 15: predose of lenvatinib; 1, 2, 4, 8, and 24 hours postdose of lenvatinib</time_frame>
    <description>Blood samples will be collected at the designated time points. The apparent volume of distribution gives information about the amount of lenvatinib distributed in body tissue rather than the blood/plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean measured concentration at the end of a dosing interval (Ctrough) of pembrolizumab</measure>
    <time_frame>Day 1 of Cycles 1, 2, 4, 6, and 8 and Day 1 in every 4 cycles after Cycle 8: predose of pembrolizumab. End of treatment: within 30 days after discontinuation or until the initiation of other anticancer treatment, whichever is earlier</time_frame>
    <description>Blood samples will be collected at the designated time points. Ctrough is the minimum concentration at the end of the dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean clearance (CL) of pembrolizumab</measure>
    <time_frame>Day 1 of Cycles 1, 2, 4, 6, and 8 and Day 1 in every 4 cycles after Cycle 8: predose of pembrolizumab. End of treatment: within 30 days after discontinuation or until the initiation of other anticancer treatment, whichever is earlier</time_frame>
    <description>Blood samples will be collected at the designated time points. Apparent clearance is defined as the rate of pembrolizumab elimination divided by serum concentration, giving a volume of plasma from which drug is completely removed per unit of time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with anti-drug antibodies (ADA) for pembrolizumab</measure>
    <time_frame>Day 1 of Cycles 1 and 6: predose of pembrolizumab</time_frame>
    <description>Blood samples will be collected and analyzed. Serum ADA will be detected by using validated methods.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>lenvatinib 8 or 12 mg plus pembrolizumab 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive oral lenvatinib at a starting dose of 8 or 12 milligrams (mg) once a day (QD) in combination with intravenous pembrolizumab 200 mg every 3 weeks (Q3W) on a 21-day treatment cycle. The starting dose of lenvatinib will be based on Baseline body weight. Participants weighing greater than or equal to 60 kilograms (kg) will receive 12 mg QD; participants weighing less than 60 kg will receive 8 mg QD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lenvatinib</intervention_name>
    <description>4 mg capsules</description>
    <arm_group_label>lenvatinib 8 or 12 mg plus pembrolizumab 200 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pembrolizumab (200 mg)</intervention_name>
    <description>30-minute intravenous infusion</description>
    <arm_group_label>lenvatinib 8 or 12 mg plus pembrolizumab 200 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of hepatocellular carcinoma (HCC)

          -  HCC for which no other appropriate therapy is available. Note: Expansion Part: No
             prior systemic therapy for advanced/unresectable HCC

          -  Stage B (not applicable for transarterial chemoembolization [TACE]), or stage C based
             on Barcelona Clinic Liver Cancer (BCLC) staging system

          -  At least 1 measurable target lesion according to modified Response Evaluation Criteria
             in Solid Tumors (mRECIST)

          -  Child-Pugh score A

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 1

          -  Total triiodothyronine (T3) or free T3 and free thyroxine (T4) are within normal
             limits. (control by thyroid replacement therapy is acceptable.) Participants with T3,
             free T3 or free T4 abnormalities at screening who are asymptomatic can be eligible

          -  Adequately controlled blood pressure

          -  Adequate renal function

          -  Adequate bone marrow function

          -  Adequate blood coagulation function

          -  Adequate liver function

          -  Males or females age â‰¥ 18 years at the time of informed consent

          -  Voluntary agreement to provide written informed consent and the willingness and
             ability to comply with all aspects of the protocol

        Exclusion Criteria:

          -  Prior treatment with lenvatinib or any anti-PD-1, anti-PD-L1, or anti-PD-L2 agent

          -  Any current brain or subdural metastases

          -  Active malignancy (except for HCC or definitively treated melanoma in-situ, basal or
             squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix) within the
             past 36 months

          -  Any medical or other condition which, in the opinion of the investigator, would
             preclude participation in a clinical trial

          -  Active infection (any infection requiring systemic treatment). Hepatitis B or C
             [HBV/HCV] is allowed

          -  Participants with CNS metastases are not eligible, unless they have completed local
             therapy (eg, whole brain radiation therapy [WBRT], surgery or radiosurgery) and have
             discontinued the use of corticosteroids for this indication for at least 4 weeks
             before starting treatment in this study. Any signs (eg, radiologic) or symptoms of
             brain metastases must be stable for at least 4 weeks before starting study treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Customer Joy Department. EJ</last_name>
    <phone>81-120-161-454</phone>
    <email>esi_medinfo@eisai.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pacific Hematology and Oncology Associates</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site</name>
      <address>
        <city>Sayama</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 27, 2016</study_first_submitted>
  <study_first_submitted_qc>December 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2016</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>E7080</keyword>
  <keyword>lenvatinib</keyword>
  <keyword>pembrolizumab</keyword>
  <keyword>Japan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

